Physician profile
Albert Lai
NPI 1154385961
$11,298.32
in general payments reported to CMS, 2019-2025
25 companies · $24.38 in 2025
The $24.38 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,105 · 2020: $331 · 2021: $490 · 2022: $804 · 2023: $1,108 · 2024: $436 · 2025: $24.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $6,341.19 | 2019-2022 | |
| Mdd US Operations, LLC | $1,295.39 | 2019 | |
| Boston Scientific Corporation | $915.78 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $787.00 | 2019-2024 | Proclaim, Octrode, Eterna |
| Medtronic, INC. | $700.20 | 2021-2023 | Intellis Adaptivestim, Accuguide |
| Forte Bio-Pharma LLC | $462.94 | 2023-2024 | Prolate, Nalocet |
| Allergan, INC. | $234.72 | 2019-2022 | |
| Medtronic USA, INC. | $106.62 | 2019-2020 | |
| Curonix LLC | $63.32 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.29 | 2020 | |
| Nevro Corp. | $45.46 | 2019-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $40.19 | 2019 | |
| Pfizer INC. | $35.96 | 2019 | |
| Vertos Medical, INC. | $33.33 | 2022 | |
| Nalu Medical, INC. | $23.45 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $21.81 | 2019 | |
| Si-Bone, INC. | $20.92 | 2019 | |
| Cequr Corporation | $20.16 | 2023 | Cequr Simplicity |
| Lilly USA, LLC | $19.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.03 | 2019 | |
| Assertio Therapeutics, INC. | $17.01 | 2019 | |
| Daiichi Sankyo INC. | $16.06 | 2019 | |
| Avanos Medical | $14.81 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.